Liver Transplantation Clinical Trial
Official title:
Insulin Therapy for Postreperfusion Hyperglycemia in Liver Transplantation
Glycemic control during liver transplantation is challenging especially after reperfusion of the liver graft. Insulin dose to treat postreperfusion hyperglycemia is retrospectively analyzed using historical data. The proposed dose then is prospectively applied to the patients to assess the adequacy of the insulin dose.
Hyperglycemia is common during liver transplantation ,especially after graft reperfusion. Response to insulin is frequently unpredictable during postreperfusion period with no consensus or guidelines on glycemic control. The primary aim of this mixed retrospective/prospective study is to investigate the optimal insulin dose to treat hyperglycemia during the postreperfusion period of liver transplantation. In the retrospective study, adult liver recipients (>18 years old) who underwent liver transplantation between 2004 and 2016 are reviewed. Delta glucose is the primary outcome variable defined as the difference in blood glucose levels before and after insulin administration. The relationship between the insulin dose and delta glucose is analyzed with a linear mixed effects analysis to find the optimal insulin dose to treat postreperfusion hyperglycemia. In the prospective trial, the proposed insulin dose is administered to the patient who showed hyperglycemia after graft reperfusion. The frequency and magnitude of glucose reduction is the primary outcome. The secondary outcome is the incidence and degree of hypoglycemia. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04180735 -
Intestinal Perforation in Patients Receiving an Orthtopic Liver Transplantation in the Montpellier University Hospital
|
||
| Completed |
NCT01011205 -
Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation
|
Phase 3 | |
| Completed |
NCT01888432 -
Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants
|
Phase 3 | |
| Recruiting |
NCT04203004 -
HOPE With Cytokine Filtration in Liver Transplantation (Cyto-HOPE)
|
N/A | |
| Recruiting |
NCT04564313 -
Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation
|
Phase 1 | |
| Not yet recruiting |
NCT02544906 -
Propofol Versus Dexmedetomidine for Prevention of Sevoflurane Agitation in Recipients of Living Donor Liver Transplantation
|
N/A | |
| Withdrawn |
NCT03596970 -
Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.
|
Phase 3 | |
| Completed |
NCT03133065 -
Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs
|
Phase 4 | |
| Recruiting |
NCT01705015 -
Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement
|
N/A | |
| Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 | |
| Completed |
NCT01425385 -
Autoregulation Assessment During Liver Transplantation
|
N/A | |
| Terminated |
NCT01445236 -
Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance
|
N/A | |
| Completed |
NCT00938860 -
Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C
|
Phase 4 | |
| Completed |
NCT00531921 -
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
|
N/A | |
| Withdrawn |
NCT00585429 -
Evaluation of Kidney Disease in Liver Transplant Recipients
|
N/A | |
| Completed |
NCT00456235 -
Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors
|
Phase 4 | |
| Terminated |
NCT00585858 -
Cytokine Kinetics Test to Assess the Presence or Absence of Tolerance in Organ Transplant
|
N/A | |
| Recruiting |
NCT00147459 -
Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation
|
N/A | |
| Withdrawn |
NCT00167492 -
Enteric Coated Myfortic for Liver Transplant Recipients
|
Phase 4 | |
| Terminated |
NCT00161356 -
Ambisome in Liver Transplant Patients
|
Phase 4 |